Cystic Fibrosis

Top Story

Pliant Therapeutics raises $62 million for proof-of-concept fibrosis studies

July 16, 2018

Anthera halts development of EPI drug candidate Sollpura

March 13, 2018
Anthera Pharmaceuticals announced it will discontinue the development of Sollpura after the drug failed to meet the primary endpoint of a phase 3 trial. Sollpura…
In the Journals Plus

Oral therapy as safe, effective as insulin in cystic fibrosis-related diabetes

December 7, 2017
Patients with cystic fibrosis-related diabetes treated with oral repaglinide for 24 months experienced improvements in HbA1c and pulmonary function that were similar to…
In the Journals

Orkambi yields positive results in younger patients with cystic fibrosis

June 12, 2017
Orkambi improved lung function in patients 6 to 11 years old with cystic fibrosis within 15 days of treatment, according to phase 3 trial results recently published in…
More Headlines »
Special Issue Article

Cystic Fibrosis–Related Diabetes in Children: An Update

Pediatric Annals, September 2016, Volume 45 Issue 9
Cystic fibrosis–related diabetes mellitus (CFRD) is the most common endocrine complication of cystic fibrosis (CF)…
More »
Video
Meeting News

VIDEO: Interstitial lung disease on the rise in patients with RA, despite better control of RA

May 11, 2017
More »
Healio Jobs